Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation

Stress Test And Cash Crunch Continues

 
• By Brian Yang

Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.

Stressed
Biogen's return of rights shows tough road remains ahead for Chinese biotech innovation • Source: Shutterstock

More from Deals

More from Business